Lupin inks strategic deal with NeuClone for cell line technology

Pharma major, Lupin has entered into a strategic licensing agreement with Sydney based private specialty life science company NeuClone for their cell line technology.

Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in oncology to its partner. The agreement will also entail the Lupin Biological Research program scientific research staff working with NeuClone terms at their facility as per a part of the overall technology transfer arrangements as specified within the agreement. This exclusive licensing agreement with NeuClone is a part of that strategy and would enable Lupin to capitalize on cutting edge technology to address the biological markets.

Lupin is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs.

NeuClone is an Australian biotech company specializing in cell line engineering for the bio-pharmaceutical and bio-manufacturing industries. NeuClone has developed technology in recombinant protein production.